FDA na-achọ iwu CBD ọhụrụ

site Ndị otu Inc.

cbd mgbakwunye

Nchịkwa nri na ọgwụ ọjọọ US (FDA) mepere emepe emepe usoro iwu ọhụrụ maka cannabidiol (CBD), dị ka onye ọrụ ụlọ ọrụ na-ekwu okwu na RAPS Convergence 2023.

"FDA na-agba mbọ maka ụda, atumatu sayensị dabeere na CBD," Owen McMaster, onye na-enyocha ọgwụ ọgwụ / toxicology na Office of Infectious's Division of Pharm / Tox for Diseases (DPT-ID) kwuru. Ọrịa (OID) na Ụlọ ọrụ FDA maka nyocha na nyocha ọgwụ (CDER). "Anyị na-atụ anya ịrụ ọrụ na Congress na ụzọ ọhụrụ ga-aga n'ihu - mbelata mmerụ ahụ na usoro nhazi."

Ọtụtụ narị ngwaahịa cannabis ọhụrụ

Mmasị nke ngwaahịa cannabis na sativa cannabis abawanyela n'ime afọ iri gara aga. FDA anatala ngwa 50 Investigation New Drug (IND) maka ngwaahịa metụtara cannabis n'ime afọ 800 gara aga, gụnyere ngwa IND 400 n'ime afọ 10 gara aga. Ụlọ ọrụ ahụ nwere IND 150 na-arụ ọrụ ugbu a na mpaghara nke ahụ riri ahụ, mgbu, ọgwụ, akwara ozi, immunology na mbufụt, McMaster gwara RASP.org.

CBD ugbu a nwere atụmatụ nha ahịa nke opekata mpe ijeri $ 4. Ọ bụrụ na ụlọ ọrụ ahụ na-enye ntụzịaka otu CBD enwere ike ree ya n'enweghị nsogbu, a na-atụ anya na nke a ga-abawanye ngwa ngwa karịa ugbu a. Nke a na-achọ ezigbo ụkpụrụ.

McMaster kọwara na FDA anatala ọtụtụ arịrịọ ụmụ amaala na-arịọ ka ụlọ ọrụ kwe ka ịhazi ngwaahịa CBD ka ọ bụrụ mgbakwunye nri. "N'ụzọ dị mwute, usoro nhazi usoro dị ugbu a anyị nwere maka nri na mgbakwunye adịghị mma maka cannabidiol. O doghị anya ka ngwaahịa CBD nwere ike isi mezuo ụkpụrụ nchekwa maka mgbakwunye nri ma ọ bụ mgbakwunye nri, "ka ọ kọwara.

Ụkpụrụ nchekwa CBD

"N'ịchịkwa ọgwụ, FDA na-eji ọkọlọtọ nchekwa na-atụle ihe ize ndụ na uru maka ndị mmadụ n'otu n'otu nwere ọnọdụ ahụike kpọmkwem, ebe ihe mgbakwunye nri na-eji" otu ìgwè sara mbara" nke ndị mmadụ na-achọ imeju nri na ịnọgide na-ahụ ike. Ụkpụrụ maka nri na ihe mgbakwunye nri bụ na ngwaahịa ahụ nwere atụmanya ezi uche maka nchekwa. "A naghị echebara uru ndị ahụ."

Ndị otu na-arụ ọrụ na-arụ ọrụ nyocha nyocha na ngwaahịa CBD metụtara, dị ka Epidiolex, wepụtara nkwupụta na Jenụwarị 2023 na-akọwa echiche ha n'azụ nkwubi okwu na CBD enweghị ike iru ụkpụrụ nchekwa maka mgbakwunye nri ma ọ bụ ihe mgbakwunye nri. Atụmatụ gụnyere enweghị ihe akaebe na ọkwa oriri dị mma maka CBD yana maka ogologo oge oriri. Ndị otu na-arụ ọrụ ahụtakwara ihe egwu metụtara inye CBD anụmanụ, yana ihe egwu nwere ike ime maka ndị mmadụ na-eri anụ, mmiri ara ehi na akwa sitere na anụmanụ nyere CBD.

“Ekwesịrị ka e mepụta ụzọ usoro iwu ọhụrụ. "Ụzọ usoro iwu ọhụrụ ga-abara ndị na-azụ ahịa uru site n'inye ihe nchekwa na nleba anya iji jikwaa na ibelata ihe egwu metụtara ngwaahịa CBD."

Agbanyeghị, achọrọ ikike sitere na Congress tupu FDA amalite ọrụ ya na mpaghara a. N'October 2022, White House wepụtara nkwupụta na-arịọ onye odeakwụkwọ ahụike na ọrụ mmadụ na United States ka ha nyochaa ka esi ahazi cannabis n'okpuru iwu gọọmentị etiti. Mkpebi sitere na nchịkwa mmanye ọgwụ ọjọọ na-echere.

Ka ọ dị ugbu a, McMaster gosiri na FDA na-agba mbọ na mbọ mmanye na-elekwasị anya ọgwụ ndị nwere nnukwu ihe egwu.

Isi: rasp.org (EN)

Ihe ndị metụtara ya

Hapụ ikwu

[ọkọlọtọ adrate = "89"]